Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

267 Press Releases
DateTitleCompany
06 Jun 14 Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism Boehringer Ingelheim,
Published by
Business Wire
05 Jun 14 European Medicines Agency (EMA) accepts accelerated marketing authorisation application for nintedanib in IPF Boehringer Ingelheim
05 Jun 14 EMA accepts marketing authorisation application for nintedanib* in IPF Boehringer Ingelheim,
Published by
Business Wire
02 Jun 14 New data show Giotrif® (afatinib) provided more than one year additional survival for lung cancer patients with the most common type of EGFR mutation (del19) compared to chemotherapy Boehringer Ingelheim,
Published by
Business Wire
27 May 14 IPF Phase III trial results published in New England Journal of Medicine (NEJM) show nintedanib* slows disease progression by approximately 50% compared with placebo Boehringer Ingelheim
23 May 14 Type 2 Diabetes: European Commission approves Jardiance® (empagliflozin) Boehringer Ingelheim,
Published by
Business Wire
21 May 14 COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva®) alone Boehringer Ingelheim,
Published by
Business Wire
15 May 14 New analysis shows Boehringer Ingelheim’s Giotrif® (afatinib) is the first treatment to demonstrate significant overall survival benefit for patients with a specific type of lung cancer Boehringer Ingelheim
15 May 14 Giotrif® (afatinib) is the first treatment to demonstrate significant overall survival benefit for patients with a specific type of lung cancer, compared to chemotherapy Boehringer Ingelheim
30 Apr 14 Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference Boehringer Ingelheim,
Published by
Business Wire
29 Apr 14 Boehringer Ingelheim and AmeriCares Partner in New Extension of Product Donations Program for the Uninsured Boehringer Ingelheim Pharmaceuticals Inc.,
Published by
Business Wire
28 Apr 14 Positive CHMP opinion for Pradaxa® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots Boehringer Ingelheim,
Published by
Business Wire
08 Apr 14 FDA approves Pradaxa® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) Boehringer Ingelheim,
Published by
Business Wire
06 Mar 14 Pradaxa® (dabigatran etexilate) now approved in over 100 countries for stroke prevention in atrial fibrillation Boehringer Ingelheim,
Published by
Business Wire
01 Mar 14 New Phase III data demonstrate tiotropium Respimat® improves lung function versus placebo and is well tolerated in asthma patients Boehringer Ingelheim
01 Mar 14 ASTHMA: New Phase III data show tiotropium* Respimat® effective across asthma severities Boehringer Ingelheim,
Published by
Business Wire
29 Jan 14 Pcovery expands investor base with corporate investor Boehringer Ingelheim Venture Fund Boehringer Ingelheim
17 Dec 13 New data on safety and efficacy of Pradaxa® in treatment of acute deep vein thrombosis and pulmonary embolism Boehringer Ingelheim,
Published by
Business Wire
16 Dec 13 Hepatitis C: Phase III data show Boehringer Ingelheim’s faldaprevir* is effective even in patients with common drug-resistant viral variant Boehringer Ingelheim,
Published by
Business Wire
09 Dec 13 Boehringer Ingelheim Scores Perfect 100 in Human Rights Campaign’s Corporate Equality Index Boehringer Ingelheim,
Published by
Business Wire
19 Nov 13 Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa® (dabigatran etexilate) in expanded patient populations Boehringer Ingelheim,
Published by
Business Wire
19 Nov 13 New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years Boehringer Ingelheim,
Published by
Business Wire
18 Nov 13 First human data show promise of Boehringer Ingelheim’s specific antidote for immediate, complete and sustained reversal of Pradaxa®-induced anticoagulation Boehringer Ingelheim
18 Nov 13 First human data show promise of Boehringer Ingelheim’s specific antidote for immediate, complete and sustained reversal of Pradaxa®-induced anticoagulation Boehringer Ingelheim,
Published by
Business Wire
07 Nov 13 New data presented at AASD further demonstrate benefits of Trajenta® (linagliptin) with efficacy and safety in specific patient populations Boehringer Ingelheim,
Published by
Business Wire
28 Oct 13 New efficacy and safety data adds to evidence supporting treatment with afatinib* (GIOTRIF®) in Asian and non-Asian lung cancer patients Boehringer Ingelheim,
Published by
Business Wire
18 Oct 13 New once-daily Striverdi* (olodaterol) Respimat® gains approval in first EU countries Boehringer Ingelheim,
Published by
Business Wire
14 Oct 13 Boehringer Ingelheim submits nintedanib*, a novel oncology compound, for European approval Boehringer Ingelheim,
Published by
Business Wire
30 Sep 13 Nintedanib* extended survival beyond one year for advanced adenocarcinoma patients after prior first-line chemotherapy Boehringer Ingelheim,
Published by
Business Wire
27 Sep 13 New Irish online COPD resource at the click of a button Boehringer Ingelheim,
Published by
Porter Novelli
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.